Nicholas Kadysh, a former Red Bull Canada and Juul Labs Canada executiveis an expert in regulatory issues
VANCOUVER, 09 Dec. 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“clear mind“or the”vsinsult“), a biotechnology company focused on the discovery and development of novel psychedelic-derived therapies to address major under-treated health issues, today announced the appointment of veteran regulatory executive Nicholas Kadysh as Special Advisor to the development of MEAI as an alcohol substitute.
Kadysh, a former executive at Red Bull Canada and Juul Labs Canada, is a career expert on managing complex regulatory challenges in the health and food industry. He is the founder of PharmAla Biotech, which manufactures MDMA and MDXX class molecules for pharmaceutical research, and the Chairman of the Board of Psychedelics Canada, the trade association of the for-profit legal Canadian psychedelic industry.
“Nick brings invaluable business and regulatory knowledge to the business. We are excited to have him join the company and bring his vast experience to our alcohol substitution program,” said Dr. Adi Zuloff-Shani. , CEO of Clearmind.
Alongside the development of its innovative new psychedelic-derived drug candidate MEAI for the treatment of addictions, Clearmind is also building a parallel pathway in which MEAI is being deployed as a substitute for alcohol. The company is currently carrying out the safety studies for this.
According to NielsenIQ, a global information services company, sales of soft drinks are growing rapidly. Between August 2021 and August 2022, total dollar sales of non-alcoholic beverages in the United States were $395 million, representing growth of approximately 21% year-on-year.
About clear mind Medicine Inc.
Clearmind Medicine (Nasdaq: CMND), (CSE: CMND), (FSE: CWY), is a biotechnology company focused on the discovery and development of novel psychedelic-derived therapies to address widespread and underserved health conditions. MEAI, the company’s lead patented molecule, is being researched as a potential solution to alcohol addiction and has already demonstrated early evidence of reducing binge behaviors that can lead to abuse. alcohol and drugs. The Company’s intellectual portfolio currently consists of seven patent families. The company’s primary focus is to research and develop psychedelic-based compounds and market them as regulated drugs, foods or supplements.
For more information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Phone: (604) 260-1566
General Information
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” and similar expressions or variations of these words are intended identify forward-looking statements. For example, the Company uses forward-looking statements when discussing the production of clinical batches of its new psychedelic-derived drug candidate, the Company’s upcoming FIH clinical trial, and any future correspondence with the FDA. Forward-looking statements are not historical facts and are based on management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. These expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be realized, and actual results may differ materially from what is expressed or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to , the risks detailed in the company’s Final Prospectus (Registration No. 333-265900) filed with the SEC on November 16, 2022. Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting the forward-looking information, except to the extent required by applicable securities laws. If the Company updates one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and information contained on such websites is not incorporated by reference in this press release. Clearmind is not responsible for the content of third party websites.
#Israeli #biotech #Clearmind #Medicine #appoints #exRed #Bull #executive #special #advisor #development #MEAI #alcohol #substitute